Epcoritamab Plus R2 Cuts Risk of Progression by 80% in Phase 3 Follicular Lymphoma Trial

Overview

• The randomized study in 488 relapsed or refractory patients showed epcoritamab plus rituximab–lenalidomide reduced the risk of progression or death by nearly 80% versus R2 alone at a median follow‑up just under 15 months.
• Response depth improved with an overall response rate of 95.1% and complete responses in 82.7%, compared with 79.2% and 49.8% for R2.
• At 16 months, progression‑free survival was 85.5% with the triplet versus 40.2% with R2, and 92.8% of patients on the triplet remained free from new anti‑lymphoma treatment.
• Grade 3–4 adverse events occurred more often with the triplet (90.1% vs 67.6%), primarily neutropenia and infections, while cytokine release syndrome was mostly low grade with no grade 3–4 cases reported.
• The results supported FDA approval in November 2025 for epcoritamab with R2 as a second‑line option delivered subcutaneously in outpatient settings, with a three‑dose step‑up schedule lowering low‑grade CRS versus a two‑dose approach.